Biomarker Serum Biobank for Glomerular Disease

Overview

About this study

The purposee of this study is to identify patients with biopsy-proven renal diseases that might have antibodies directed against kidney-antigens, or other circulating biomarkers, that contribute to disease pathogenesis including, but not limited to: amyloidosis, acute tubular necrosis, diabetic nephropathy, focal segmental glomerular sclerosis, IgA nephropathy, interstitial nephritis, membranous nephropathy, minimal change disease, immunoglobulin- and complement-mediated glomerular disease, and ANCA vasculitis.  Serum (up to 10 ml) will be obtained within two weeks of renal biopsy either as waste from the Mayo Clinic Rochester Central Clinical Laboratory or a referring laboratory, or if stored serum is not available from a prospective blood draw after patient consent.  The serum will be biobanked in the Clinical Specialty Laboratory for current and future test development and/or research studies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with adequate clinical residual serum ( ≥ 0.5 mcL) or prospectively drawn blood obtained within 10 days of native renal biopsy, and prior to initiation of immunosuppressive therapy. 
  • The glomerular diseass of interest occur in varied patient populations; therefore, both adult and pediatric patients will be enrolled.   

Exclusion Criteria:

  • Does not meet Inclusion Criteria.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/14/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Open for enrollment

Contact information:

John Lieske M.D.

(507) 284-2064

Lieske.John@mayo.edu

More information

Publications

Publications are currently not available